These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22075318)

  • 1. Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis.
    Trad S; Huong du LT; Frances C; Wechsler B; Cacoub P; Costedoat N; Haroche J; Piette JC; Hanslik T; Amoura Z
    Eur J Intern Med; 2011 Dec; 22(6):e80-6. PubMed ID: 22075318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study].
    Liu QX; Zheng JP; Xie YQ; Guan WJ; Jiang CY; An JY; Yu XX; Liu WT; Gao Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):510-5. PubMed ID: 24262087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
    Steen V; Medsger TA
    Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different diffusing capacity of the lung for carbon monoxide as predictors of respiratory morbidity.
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2009 Aug; 88(2):405-10; discussion 410-1. PubMed ID: 19632384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
    Pernot J; Puzenat E; Magy-Bertrand N; Manzoni P; Gondouin A; Bourdin H; Simon-Rigaud ML; Regnard J; Degano B
    Respiration; 2012; 84(6):461-8. PubMed ID: 22301769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane.
    Guazzi M; Agostoni P
    Clin Sci (Lond); 1999 Jan; 96(1):17-22. PubMed ID: 9857102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
    Someya F; Mugii N; Hasegawa M; Yahata T; Nakagawa T
    Respir Care; 2014 Jan; 59(1):75-80. PubMed ID: 23764864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lung involvement in systemic sclerosis].
    Quadrelli S; Ciallella L; Catalán Pellet AC; Molinari L; Salvado A; Auad C; Spina JC
    Medicina (B Aires); 2007; 67(5):429-35. PubMed ID: 18051224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusing Pulmonary Capacity Measured During Effort: A Possible Early Marker of Pulmonary Involvement In Systemic Sclerosis.
    Legnani D; Rizzi M; Sarzi-Puttini P; Cristiano A; La Spina T; Frassanito F; Airoldi A; Atzeni F
    Isr Med Assoc J; 2015 Dec; 17(12):739-43. PubMed ID: 26897974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Change of pulmonary diffusing capacity, membrane diffusing capacity and pulmonary capillary blood volume in patients with COPD and connective tissue disease at rest and post-exercise].
    Chi L; Liu Y; Piao Z
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jun; 21(6):344-7. PubMed ID: 11326890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC; Highland KB; Silver RM; Strange C
    J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance capacity evaluated using the 6-minute walk test: 5-year results in patients with diffuse systemic sclerosis and initial interstitial lung disease.
    Rizzi M; Sarzi-Puttini P; Airoldi A; Antivalle M; Battellino M; Atzeni F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S142-7. PubMed ID: 26339893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
    Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
    Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophageal involvement and pulmonary manifestations in systemic sclerosis.
    Marie I; Dominique S; Levesque H; Ducrotté P; Denis P; Hellot MF; Courtois H
    Arthritis Rheum; 2001 Aug; 45(4):346-54. PubMed ID: 11501722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.